Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic ...Show More
peer of
Metrics
marketSTOCKS
msh_idCOM:CURIS
localeus
websitehttps://www.curis.com
ipo_date2000-08-01
primary_stock_msh_idNASDAQ:CRIS
source_ref3cc48ef5-1248-4cc1-b580-42a090bc1e71
company_size11
products_or_servicesTherapeutics for cancer treatment including Emavusertib (CA-4948), Fimepinostat, and CA-170 among others.